Coronary stents, dual antiplatelet therapy and peri-operative problems

被引：16

作者：

Metzler H. ^{[1
,4
]}

Huber K. ^{[2
]}

Kozek-Langenecker S. ^{[3
]}

Vicenzi M.N. ^{[1
]}

Münch A. ^{[1
]}

机构：

[1] Universitätsklinik für Anästhesiologie und Intensivmedizin, Medizinische Universität Graz, Graz

[2] 3. Medizinische Abteilung Mit Kardiologie und Internistischer Notaufnahme, Wilhelminenspital, Wien

[3] Universitätsklinik für Allgemeine Anästhesie und Intensivmedizin B, Medizinische Universität Wien, Wien

[4] Universitätsklinik für Anästhesiologie und Intensivmedizin, Medizinische Universität Graz, Graz 8036

来源：

Der Anaesthesist | 2007年 / 56卷 / 4期

关键词：

Coronary stent implantation; Dual antiplatelet drug therapy; Percutaneous coronary intervention; Perioperative stent thrombosis; Regional anaesthesia;

D O I：

10.1007/s00101-007-1171-3

中图分类号：

学科分类号：

摘要：

Up to 90% of all percutaneous coronary interventions include coronary artery stenting. Dual antiplatelet therapy, usually involving acetylsalicyl acid combined with clopidogrel, is mandatory for patients with coronary artery stents. The duration of antiplatelet therapy for bare metal stents is 3-4 weeks, for drug eluting stents 6-12 months. Preoperative discontinuation of both drugs increases the risk of stent thrombosis, continuation the risk of relevant bleeding. According to the recommendations of anaesthesiological and cardiological societies, perioperative management has to balance the risk of bleeding vs stent thrombosis. Surgery involving a high risk of bleeding can require the discontinuance of both substances. In cases of high thrombosis risk, at least the acetylsalicyl acid should be continued until the day of surgery. For patients under antiplatelet therapy scheduled for local anaesthesia, national recommendations exist. A close collaboration between the anaesthesiologist, cardiologist and surgeon is essential for appropriate pre-, intra- and postoperative management. © 2007 Springer Medizin Verlag.

引用

页码：401 / 412

页数：11

共 44 条

[1] Guideline update for perioperative cardiovascular evaluation for noncardiac surgery - executive summary, J Am Coll Cardiol, 39, pp. 542-553, (2002)
[2] Agarwal S., Coakely M., Reddy K., Quantifying the effect of antiplatelet therapy: A comparison of the platelet function analyzer (PFA-100® ) and modified thrombelastography (mTEG® ) with light transmission platelet aggregometry, Anesthesiology, 105, pp. 676-683, (2006)
[3] Al Suwaidi J., Berger P.B., Holmes D.R., Coronary artery stents, JAMA, 284, pp. 1828-1836, (2000)
[4] Ascione R., Gosh A., Rogers C.A., Et al., In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: A word of caution, Ann Thorac Surg, 79, pp. 1210-1216, (2005)
[5] Auerbach A., Goldman L., Assessing and reducing the cardiac risk of noncardiac surgery, Circulation, 113, pp. 1361-1376, (2006)
[6] Beck K.H., Mohr P., Bleckmann U., Desmopressin effect on acetylsalicylic acid impaired platelet function, Semin Thromb Hemost, 21, SUPPL. 2, pp. 32-39, (1995)
[7] Brilakis E.S., Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery, Am J Cardiol, 96, pp. 512-514, (2005)
[8] Curfman G.D., Morrissey S., Jarcho J.A., Et al., Drug-eluting-stents - promise and uncertaincy, N Engl J Med, 356, pp. 1059-1060, (2007)
[9] Cutlip D.E., Baim D.S., Ho K.K., Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials, Circulation, 103, pp. 1967-1971, (2001)
[10] Dyszkiewicz-Korpanty A.M., Frenkel E.P., Sarode R., Approach to the assessment of platelet function: Comparison between optical-based platelet-rich plasma and impedancebased whole blood platelet aggregation methods, Clin Appl Thromb Hemost, 11, pp. 25-35, (2005)

← 1 2 3 4 5 →